Item type |
デフォルトアイテムタイプ(フル)(1) |
公開日 |
2021-11-09 |
タイトル |
|
|
タイトル |
Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer |
|
言語 |
en |
作成者 |
Tsuzuki, Shunsuke
Nakanishi, Shotaro
Tamaki, Mitsuyoshi
Oshiro, Takuma
Miki, Jun
Yamada, Hiroki
Shimomura, Tatsuya
Kimura, Takahiro
Furuta, Nozomu
Saito, Seiichi
Egawa, Shin
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利情報 |
|
|
言語 |
ja |
|
権利情報 |
© 2021 Tsuzuki et al. |
権利情報 |
|
|
言語 |
en |
|
権利情報 |
Creative Commons Attribution 4.0 |
権利情報 |
|
|
言語 |
en |
|
権利情報Resource |
https://creativecommons.org/licenses/by/4.0/ |
|
権利情報 |
https://creativecommons.org/licenses/by/4.0/ |
内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Background:There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).\nMethods:The clinical charts of 233 patients with CRPC treated with enzalutamide were reviewed retrospectively. After 1:3 propensity score matching (PSM), 124 patients were divided into a reduced dose group and a standard dose group, and the prostate specific antigen (PSA) response and the incidence of AEs were compared.\nResults:190 patients with CRPC initiated with standard dose enzalutamide were younger and better performance status compared with 43 patients beginning with reduced dose. After PSM, the baseline characteristics were not different between the standard and the reduced dose group. In the PSM cohort, the PSA response rate was significantly lower in the reduced dose group than in the standard dose group (-66.3% and -87.4%, p = 0.02). The incidence rates of AEs were not statistically different between the groups (22.6% and 34.4%, respectively, p = 0.24).\nConclusion:\nInitiating treatment with a reduced dose of enzalutamide did not significantly decrease the incidence rate of AEs, and it showed poorer PSA response rate. There is no clear rationale for treating with a reduced initial dose of enzalutamide to reduce the incidence of AEs. |
内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
論文 |
出版者 |
|
|
出版者 |
Public Library of Science |
|
言語 |
en |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
識別子 |
|
|
識別子 |
http://hdl.handle.net/20.500.12000/49966 |
|
識別子タイプ |
HDL |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1371/journal.pone.0258160 |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1371/journal.pone.0258160 |
収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1932-6203 |
収録物名 |
|
|
収録物名 |
PLoS ONE |
|
言語 |
en |
書誌情報 |
発行日 2021-10-01
|